Overview
Umbilical cord tissue therapy uses Wharton's Jelly from donated umbilical cords, which is rich in mesenchymal stem cells, growth factors, and hyaluronic acid. These components may promote healing and reduce inflammation.
In-Depth: Cord Tissue
Umbilical cord tissue therapy, specifically using Wharton's Jelly, is an allogeneic (donor-derived) regenerative treatment that utilizes tissue from the umbilical cord of healthy newborns. Wharton's Jelly is the gelatinous substance that surrounds and protects the blood vessels within the umbilical cord, and it is exceptionally rich in mesenchymal stem cells, growth factors, hyaluronic acid, collagen, and cytokines. Umbilical cord tissue is collected with informed consent from mothers after healthy, full-term births — typically planned cesarean sections — and is processed in certified tissue banks according to strict standards set by the American Association of Tissue Banks (AATB).
One of the key advantages cited by proponents of cord tissue therapy is that the mesenchymal stem cells found in Wharton's Jelly are younger and potentially more potent than stem cells harvested from an adult's bone marrow or fat tissue. Neonatal MSCs may have greater proliferative capacity and stronger anti-inflammatory and immunomodulatory properties. Additionally, because umbilical cord tissue is an immune-privileged material, the risk of immune rejection is considered to be low, allowing it to be used in patients without tissue matching. The product can be administered via injection into joints or tissues, or via intravenous infusion for systemic conditions.
However, there is significant debate and regulatory scrutiny surrounding cord tissue products. The FDA considers umbilical cord tissue products that contain live cells and are processed beyond minimal manipulation to be biological products that require FDA approval. Many cord tissue products marketed by clinics may not contain viable living stem cells by the time they reach the patient, particularly if they have been cryopreserved and then thawed. Patients should ask their provider specific questions about whether the product they are receiving contains verified live cells and what quality testing has been performed.
How It Works
- 1 Umbilical cord tissue is sourced from consenting donors after healthy births
- 2 Wharton's Jelly is processed and prepared in a certified lab
- 3 The product is injected into the treatment area or administered via IV
- 4 Growth factors and cellular components promote healing
- 5 Anti-inflammatory properties help manage chronic conditions
Best For
Risks & Side Effects
- Potential immune reactions, though cord tissue is generally considered immune-privileged
- Risk of disease transmission from donor tissue, though rigorous screening is performed
- Product may not contain viable living stem cells if improperly processed or stored
- Regulatory uncertainty — many cord tissue products have not received FDA approval
- Risk of infection at the injection or infusion site
- Cost is significant and not covered by insurance
Who Is a Good Candidate?
- May be considered: Patients who prefer not to undergo bone marrow or fat tissue harvesting procedures
- May be considered: Older patients whose own stem cells may have reduced potency
- May be considered: Patients with joint degeneration, chronic inflammation, or autoimmune conditions seeking immunomodulatory treatment
- Use caution: Patients should verify the tissue bank accreditation and product quality certifications
- Use caution: Patients should ask whether the specific product has been tested for viable cell content